"As Biogen's relentless patent defense for blockbuster multiple sclerosis med Tecfidera came up short in the U.S., the company separately worked to fend off competition through an anticompetitive kickbacks scheme, a multi-employer health benefit plan claimed in a new lawsuit.... 'Had Biogen not bribed the PBMs, the PBMs would have given generic Tecfidera more favorable placement on their formularies to promote the use of generic Tecfidera over the higher-cost Tecfidera and Vumerity,' the plaintiff's lawyers explained in the complaint." [Local No. 1 Health Fund v. Biogen, Inc., No. 24-7387 (N.D. Ill. complaint filed Aug. 16, 2024)]  MORE >>